WASHINGTON (Reuters) - Shares of Allergan Inc <AGN.N> fell 12 percent on Monday after U.S. regulators issued draft guidance that would enable generic versions of the company's dry eye drug Restasis to come to market more quickly. Full story
Allergan filed applications with U.S. and European regulators for approval to sell Botox as a treatment for overactive bladders. David Pyott, chairman & CEO of Allergan, offers insight on Botox and its many uses.
CNBC's Jim Cramer gives his take on six stocks in 60 seconds, including Oracle, Allergan, Southwest Airlines and others.
David Pyott, CEO of Allergan, speaks during the Reuters Health Summit in New York, May 9, 2011. REUTERS/Brendan McDermid